Key Points of the Collaboration:
Exclusive Rights for Ferring: Ferring Pharmaceuticals will have exclusive rights to develop, manufacture, and commercialize next-generation microbiome-based therapeutics within gastroenterology that arise from this collaboration.
Financial Details: The financial specifics of the deal have not been disclosed.
Ferring’s Commitment to Gut Microbiome Therapeutics: Carl Bilbo, Senior Vice President of Microbiome at Ferring Pharmaceuticals, emphasized the company’s long-term mission to maximize the therapeutic potential of the gut microbiome for patient benefit. He highlighted PharmaBiome’s unique technology in identifying and manufacturing defined consortium live microbiome biotherapeutics.
PharmaBiome’s Unique Technology Platform: PharmaBiome has developed a technology platform based on two core technologies, NicheMap™ and a co-cultivation approach. This platform allows for the selection of bacterial strains for designing bacterial consortia as live biotherapeutic products with defined activities.
Ferring’s Track Record: Ferring is noted for being the first company to bring forward a first-in-class FDA-approved live microbiome-based therapy to US patients. The company has a proven ability to drive clinical trials and manufacture microbiome-based products.
PharmaBiome’s Expertise: PharmaBiome specializes in developing therapeutic consortia using gut bacteria for targeted modification of the microbiome composition and activity. The company’s drug-development platform includes an in vitro culture-based technology.
This collaboration represents a significant step in advancing microbiome-based therapeutics in gastroenterology, combining Ferring’s experience in bringing therapies to market with PharmaBiome’s innovative technology in microbiome research.